Towards personalized therapy for patients with glioblastoma

References

• Fisher JL, Schwartzbaum JA, Wrensch M, Wiemels JL. Epidemiology of brain tumors. Neurol. Clin.25(4), 867–890 (2007).
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med.352(10), 987–996 (2005).
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens AC, Gorlia T et al.MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med.352(10), 997–1003 (2005).
   PubMed Web of Science ®Google Scholar
• Mirimanoff RO, Gorlia T, Mason W et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 Phase III randomized trial. J. Clin. Oncol.24(16), 2563–2569 (2006).
   PubMed Web of Science ®Google Scholar
• Curran WJ Jr, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant gliomas trials. J. Natl. Cancer Inst.85(9), 704–710 (1993).
   PubMed Web of Science ®Google Scholar
• Werner MH, Phuphanich S, Lyman GH. The increasing incidence of malignant gliomas and primary central nervous system lymphoma in the elderly. Cancer76(9), 1634–1642 (1995).
   PubMed Web of Science ®Google Scholar
• Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet359(9311), 1011–1018 (2002).
   PubMed Web of Science ®Google Scholar
• Agarwala SS, Kirkwood JM. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist5(2), 144–151 (2000).
   PubMedGoogle Scholar
• Brada M, Hoang-Xuan K, Rampling R et al. Multicenter Phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann. Oncol.12(2), 259–266 (2001).
   PubMed Web of Science ®Google Scholar
• Stupp R, Dietrich PY, Ostermann KS et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J. Clin. Oncol.20(5), 1375–1382 (2002).
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized Phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol.10(5), 4189–4199 (2009).
   Google Scholar
• Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res.59(4), 793–797 (1999).
   PubMed Web of Science ®Google Scholar
• Hegi ME, Liu L, Herman JG et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J. Clin. Oncol.26(25), 4189–4199 (2008).
   PubMed Web of Science ®Google Scholar
• Quinn JA, Pluda J, Dolan ME et al. Phase II trial of carmustine plus O6-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J. Clin. Oncol.20(9), 2277–2283 (2002).
   PubMed Web of Science ®Google Scholar
• Quinn JA, Jiang SX, Reardon DA et al. Phase II trial of temozolomide plus O6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J. Clin. Oncol.27(8), 1262–1267 (2009).
   PubMed Web of Science ®Google Scholar
• Tolcher AW, Gerson SL, Denis L et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br. J. Cancer88(7), 1004–1011 (2003).
   PubMed Web of Science ®Google Scholar
• Clarke JL, Iwamoto FM, Sul J et al. Randomized Phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J. Clin. Oncol.27(23), 3861–3867 (2009).
   PubMed Web of Science ®Google Scholar
• Brada M, Stenning S, Gabe R et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. J. Clin. Oncol.28(30), 4601–4608 (2010).
   PubMed Web of Science ®Google Scholar
• Nicholas MK, Lukas RV, Jafri NF, Faoro L, Salgia R. Epidermal growth factor receptor – mediated signal transduction in the development and therapy of gliomas. Clin. Cancer Res.12(24), 7261–7270 (2006).
   PubMed Web of Science ®Google Scholar
• Rich JN, Reardon DA, Peery T et al. Phase II trial of gefitinib in recurrent glioblastoma. J. Clin. Oncol.22(1), 133–142 (2004).
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Brandes AA, Rampling R et al. Randomized Phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J. Clin. Oncol.27(8), 1268–1274 (2009).
   PubMed Web of Science ®Google Scholar
• Chakravarti A, Berkey B, Robins H et al. An update of Phase II results from RTOG0211: a Phase I/II study of gefitinib with radiotherapy in newly diagnosed glioblastoma. J. Clin. Oncol.24(Suppl. 18), 1527 (2006).
   Google Scholar
• Brown PD, Krishnan S, Sarkaria JN et al. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J. Clin. Oncol.26(34), 5603–5609 (2008).
   PubMed Web of Science ®Google Scholar
• Prados MD, Chang SM, Butowski N et al. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J. Clin. Oncol.27(4), 579–584 (2009).
   PubMed Web of Science ®Google Scholar
• Stommel JM, Kimmelman AC, Ying H et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science318(5848), 287–290 (2007).
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med.350(21), 2129–2139 (2004).
   PubMed Web of Science ®Google Scholar
• Marie Y, Carpentier AF, Omuro AM et al. EGFR tyrosine kinase domain mutations in human gliomas. Neurology64(8), 1444–1445 (2005).
   PubMed Web of Science ®Google Scholar
• Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto Phase II clinical trials. J. Clin. Oncol.17(8), 2572–2578 (1999).
   PubMed Web of Science ®Google Scholar
• Mellinghoff IK, Wang MY, Vivanco I et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med.353(19), 2012–2024 (2005).
   PubMed Web of Science ®Google Scholar
• Haas-Kogan DA, Prados MD, Tihan T et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J. Natl. Cancer. Inst.97(12), 880–887 (2005).
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat. Med.9(6), 669–676 (2003).
   PubMed Web of Science ®Google Scholar
• Stefanik DF, Fellows WK, Rizkalla LR et al. Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft. J. Neurooncol.55(2), 91–100 (2001).
   PubMed Web of Science ®Google Scholar
• Bao S, Wu Q, Sathornsumetee S et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res.66(16), 7843–7848 (2008).
   Web of Science ®Google Scholar
• Vredenburgh JJ, Desjardins A, Herndon JE II et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol.25(30), 4722–4729 (2007).
   PubMed Web of Science ®Google Scholar
• Prados MD, Lamborn K, Yung WK et al. A Phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro. Oncol.8(2), 189–193 (2006).
   PubMed Web of Science ®Google Scholar
• Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol.27(28), 4733–4740 (2009).
   PubMed Web of Science ®Google Scholar
• Kreisl TN, Kim L, Moore K et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol.27(5), 740–745 (2009).
   PubMed Web of Science ®Google Scholar
• Chi AS, Norden AD, Wen PY. Antiangiogenic strategies for treatment of malignant gliomas. Neurotherapeutics6(3), 513–526 (2009).
   PubMed Web of Science ®Google Scholar
• Chen W, Delaloye S, Silverman DH et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J. Clin. Oncol.25(30), 4714–4721 (2007).
   PubMed Web of Science ®Google Scholar
• Sathornsumetee S, Cao Y, Marcello JE et al. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J. Clin. Oncol.26(2), 271–278 (2008).
   PubMed Web of Science ®Google Scholar
• Lai A, Filka E, McGibbon B et al. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int. J. Radiat. Oncol. Biol. Phys.71(5), 1372–1380 (2008).
   PubMed Web of Science ®Google Scholar
• Lai A, Tran A, Nghiemphu PL et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J. Clin. Oncol.29(2), 142–148 (2011).
   PubMed Web of Science ®Google Scholar
• Raymond E, Brandes AA, Dittrich C et al. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group study. J. Clin. Oncol.26(28), 4659–4665 (2008).
   PubMed Web of Science ®Google Scholar
• Dresemann G, Weller M, Rosenthal MA et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. J. Neurooncol.96(3), 393–402 (2010).
   PubMed Web of Science ®Google Scholar
• Dai H, Marbach P, Lemaire M, Hayes M, Elmquist WF. Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J. Pharmacol. Exp. Ther.304(3), 1085–1092 (2003).
   PubMed Web of Science ®Google Scholar
• Howes JF, Bell C. Talampanel. Neurotherapeutics4(1), 126–129 (2007).
   PubMed Web of Science ®Google Scholar
• Ishiuchi S, Tsuzuki K, Yoshida Y et al. Blockage of Ca2+-permeable AMPA receptors suppresses migration and induces apoptosis in human glioblastoma cells. Nat. Med.8(9), 971–978 (2002).
   PubMed Web of Science ®Google Scholar
• Grossman SA, Ye X, Chamberlain M et al. Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter Phase II trial. J. Clin. Oncol.27(25), 4155–4161 (2009).
   PubMed Web of Science ®Google Scholar
• Yamada S, Bu XY, Khankaldyyan V, Gonzales-Gomez I, McComb JG, Laug WE. Effect of the angiogenesis inhibitor cilengitide (EMD 121974) on glioblastoma growth in nude mice. Neurosurgery59(6), 1304–1312 (2006).
   PubMed Web of Science ®Google Scholar
• Reardon DA, Fink KL, Mikkelsen T et al. Randomized Phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J. Clin. Oncol.26(34), 5610–5617 (2008).
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, Neyns B et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J. Clin. Oncol.28(16), 2712–2718 (2010).
   PubMed Web of Science ®Google Scholar
• Stupp R, Van Den Bent M, Erridge S et al. Cilengitide in newly diagnosed glioblastoma with MGMT promoter methylation: protocol of a multicenter, randomized, open-label, controlled Phase III trial (CENTRIC). J. Clin. Oncol.28(Suppl. 15), (2010) (Abstract TPS152).
   Web of Science ®Google Scholar
• Nabors L, Fink K, Reardon D et al. Cilengitide in patients with newly diagnosed glioblastoma multiforme and unmethylated MGMT gene promoter: protocol of a multicenter, randomized, open-label, controlled Phase II study. J. Clin. Oncol.28(Suppl. 15), (2010) (Abstract TPS151).
   PubMedGoogle Scholar
• Yin D, Zhou H, Kumagai T et al. Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene24(3), 344–354 (2005).
   PubMed Web of Science ®Google Scholar
• Koschny R, Holland H, Sykora J et al. Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Clin. Cancer Res.13(11), 3403–3412 (2007).
   PubMed Web of Science ®Google Scholar
• Kubicek GJ, Werner-Wasik M, Machtay M et al. Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies. Int. J. Radiat. Oncol. Biol. Phys.74(2), 433–439 (2009).
   PubMed Web of Science ®Google Scholar
• Yin D, Ong JM, Hu J et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo. Clin Cancer Res.13(3), 1045–1052 (2007).
   PubMed Web of Science ®Google Scholar
• Galanis E, Jaeckle KA, Maurer MJ et al. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J. Clin. Oncol.27(12), 2052–2058 (2009).
   PubMed Web of Science ®Google Scholar
• Grossman SA, Ye X, Piantadosi S et al. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin. Cancer. Res.16(8), 2443–2449 (2010).
   PubMed Web of Science ®Google Scholar
• Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N. Engl. J. Med.356(15), 1527–1535 (2007).
   PubMed Web of Science ®Google Scholar
• Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J. Clin. Oncol.22(9), 1583–1588 (2004).
   PubMed Web of Science ®Google Scholar
• Lutterbach J, Ostertag C. What is the appropriate radiotherapy protocol for older patients with newly diagnosed glioblastoma? J. Clin. Oncol.23(12), 2869–2870 (2005).
   PubMed Web of Science ®Google Scholar
• Glantz M, Chamberlain M, Liu Q, Litofsky NS, Recht LD. Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas. Cancer97(9), 2262–2266 (2003).
   PubMed Web of Science ®Google Scholar
• Chinot OL, Barrie M, Frauger E et al. Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations. Cancer100(10), 2208–2214 (2004).
   PubMed Web of Science ®Google Scholar
• Malmstrom A, Grønberg BH, Stupp R et al. Glioblastoma (GBM) in elderly patients: a randomized Phase III trial comparing survival in patients treated with 6-week radiotherapy (RT) versus hypofractionated RT over 2 weeks versus temozolomide single-agent chemotherapy (TMZ). J. Clin. Oncol.28(Suppl. 18), (2010) (Abstract LBA2002).
   PubMed Web of Science ®Google Scholar
• Wick W, Engel C, Combs SE et al. NOA-08 randomized Phase III trial of 1-week-on/1-week-off temozolomide versus involved-field radiotherapy in elderly (older than age 65) patients with newly diagnosed anaplastic astrocytoma or glioblastoma (Methusalem). J. Clin. Oncol.28(Suppl. 18), (2010) (Abstract LBA2001).
   Google Scholar
• Brandes AA, Vastola F, Basso U et al. A prospective study on glioblastoma in the elderly. Cancer97(3), 657–662 (2003).
   PubMed Web of Science ®Google Scholar
• Combs SE, Wagner J, Bischof M et al. Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients. Int. J. Radiat. Oncol. Biol. Phys.70(4), 987–992 (2008).
   PubMed Web of Science ®Google Scholar
• Brandes AA, Franceschi E, Tosoni A et al. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer115(15), 3512–3518 (2009).
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Betensky RA, Esposito JM et al. Age-dependent prognostic effects of genetic alterations in glioblastoma. Clin. Cancer Res.10(1), 228–233 (2004).
   PubMed Web of Science ®Google Scholar
• Roa W, Xing JZ, Small C et al. Current developments in the radiotherapy approach to elderly and frail patients with glioblastoma multiforme. Expert Rev. Anticancer Ther.9(11), 1643–1650 (2009).
   PubMed Web of Science ®Google Scholar
• Dowsett M, Dunbier AK. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin. Cancer Res.14(24), 8019–8026 (2008).
   PubMed Web of Science ®Google Scholar